- Behçet’s disease is characterized by unpredictable flare-ups and periods of remission, making long-term management particularly challenging.
- Current treatment strategies for the disease focus on controlling inflammation and suppressing immune activity using corticosteroids, immunosuppressants and biologic agents.
- Soligenix has released positive top-line results from its phase 2 clinical trial evaluating SGX945 for the treatment of aphthous ulcers associated with Behçet’s.
Behçet’s disease is a rare, chronic inflammatory condition that can cause recurrent, painful ulcers, eye inflammation and systemic complications that significantly affect quality of life. Because available treatments are limited and often inconsistent, clinical trial updates in this disease area carry particular importance. Soligenix (NASDAQ: SNGX) is reporting results from a phase 2a proof of concept study evaluating its investigational therapy, SGX945 (dusquetide), for the treatment of Behçet’s disease, representing a notable step forward in efforts to improve care for patients with this underserved condition.
Behçet’s disease is classified as a variable vessel vasculitis, meaning it can affect blood vessels of all sizes throughout the body…
NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://nnw.fm/SNGX
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer
NetworkNewsWire
Austin, Texas
www.NetworkNewsWire.com
512.354.7000 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is powered by IBN
